Literature DB >> 9200384

Human monocytic ehrlichiosis in children.

G E Schutze1, R F Jacobs.   

Abstract

BACKGROUND: Much of what is known about human monocytic ehrlichiosis (HME) is based upon studies with adult patients.
PURPOSE: To review our experience with HME to better understand the epidemiology, clinical manifestations, and outcome of this disease in children.
METHODS: Demographic, clinical, and laboratory data were gathered after review of the medical records of patients identified with HME.
RESULTS: Twelve patients with an median age of 7.4 years (range, 7 months to 13.7 years) were identified with HME; 10 were white, 7 were male, and 10 were from hometowns of <800 people. Eight patients presented from May through July, and 8 had a history of tick bites. Symptoms demonstrated by the patients during their illness included fever (100%), rash (67%), myalgias (58%), and vomiting, diarrhea, and headache (25%). On presentation, patients demonstrated thrombocytopenia (92%), elevated liver function tests (91%), lymphopenia (75%), hyponatremia (67%), leukopenia (58%), and anemia (42%) on the initial laboratory examination. Four patients presented in shock and 3 required blood pressure support and mechanical ventilation for a median of 10 days (8 to 37 days). These complicated patients required longer hospitalization (19.5 days vs 5. 5 days) and attained higher blood urea nitrogen levels (42.5 mg/dL vs 10 mg/dL) than the patients not presenting with shock. Morbidity associated with HME patients included a decrease in cognitive and neurologic performance.
CONCLUSIONS: More information and long-term follow-up is required to understand the full spectrum of disease and morbidity associated with HME in children.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9200384     DOI: 10.1542/peds.100.1.e10

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  6 in total

Review 1.  Clinical manifestations of tick-borne infections in children.

Authors:  K A Bryant; G S Marshall
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

2.  An intradermal environment promotes a protective type-1 response against lethal systemic monocytotropic ehrlichial infection.

Authors:  Heather L Stevenson; Jeffrey M Jordan; Ziad Peerwani; Hui-Qun Wang; David H Walker; Nahed Ismail
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

Review 3.  Severe Ehrlichia chaffeensis infection in a lung transplant recipient: a review of ehrlichiosis in the immunocompromised patient.

Authors:  Nasia Safdar; Robert B Love; Dennis G Maki
Journal:  Emerg Infect Dis       Date:  2002-03       Impact factor: 6.883

4.  Diminished hematopoietic activity associated with alterations in innate and adaptive immunity in a mouse model of human monocytic ehrlichiosis.

Authors:  Katherine C MacNamara; Rachael Racine; Madhumouli Chatterjee; Dori Borjesson; Gary M Winslow
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

Review 5.  Ehrlichia chaffeensis: a prototypical emerging pathogen.

Authors:  Christopher D Paddock; James E Childs
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

6.  Ehrlichia infection of the central nervous system.

Authors:  Igen Hongo; Karen C Bloch
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.972

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.